Soo brings over 25 years of experience in the biopharmaceutical, healthcare and clinical research industry to K36. She started her career in clinical research in the academic healthcare of GWU, NYU, Winthrop Hospitals, and NYC Health and Hospitals where she managed clinical trials and led research administration activities. She transitioned into industry through Pfizer, then Celgene, where she was responsible for contracts and outsourcing across all phases of clinical trials, medical, and market access, and investigator-initiated research. At Celgene, she worked in clinical operations, then alliance management where she managed numerous complex corporate alliances across hematology/oncology, including sotatercept and luspatercept with Acceleron. Soo progressed to VP of Business Strategy & Integration, where she led a team of technical professionals in commercialization, product launch leads, project management, OpEx, and alliance management. She led late-stage oncology asset CMC transition-INREBIC® (Fedratinib) and was the transition leader for late-stage asset (Marizomib) in licensing.

 

Prior to joining K36 Therapeutics, Soo was with Bristol Myers Squibb where she led the enterprise integration management activities of the Celgene acquisition. Most recently, Soo was the SVP of Corporate and Business Development at Innovo Therapeutics and the founder of Integration Alliance Partners. 

​

​Soo holds a B.A (Honors) in Psychology and Masters in Health Administration & Finance from The George Washington University. She completed her administrative fellowship at Johns Hopkins Health System.